Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT06342401
Recruiting Observational

Early Onset Colorectal Cancer Detection

NCT06342401 · tracked via the Priya Life Science Japan tracker
Sponsor
City of Hope Medical Center
Phase
Observational
Started
2023-04-15
Last updated
2026-07-07

Condition(s) studied

Colorectal CancerColorectal NeoplasmsColorectal AdenocarcinomaColorectal Cancer Stage IColorectal Cancer Stage IVColorectal Cancer Stage IIColorectal Cancer Stage IIIColorectal Neoplasms Malignant

Investigational drug(s) / intervention(s)

ENCODE

ENCODE: A panel of microRNA, both cell-free and exosomes, whose expression level is tested from plasma samples from patients with early onset colorectal cancer and non-disease controls.

Study summary

Colorectal cancer (CRC) once predominantly affected older individuals, but in recent years has witnessed a progressive increase in incidence among young adults. Once rare, early-onset colorectal cancer (EOCRC, that is, a CRC diagnosed before the age of 50) now constitutes 10-15% of all newly diagnosed CRC cases and it stands as the first cause of cancer-related death in young men and the second for young women.

This study aims to detect EOCRC with a non-invasive test, using a blood-based molecular assay based on microRNA (ribonucleic acid)

Eligibility

Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Stage I, II, III, IV colorectal cancer (TNM classification, 8th edition) diagnosed before the age of 50 (EOCRC cases) * Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment * Colonoscopy-proven cancer-free status at the time of study inclusion (Non-disease controls) Exclusion Criteria: * Hereditary colorectal cancer syndromes (identified through genetic testing) * Inflammatory bowel diseases * Lack of written informed consent

Primary outcome measure(s)

Trial sites (13)

FacilityCityRegionStatus
City of Hope Medical Center Duarte California Recruiting
IRCCS San Raffaele Milan Italy Recruiting
Kawasaki University Kawasaki Japan Recruiting
Mie University Mie Japan Recruiting
National Cancer Center Hospital Tokyo Japan Recruiting
Tokyo Medical and Dental University Tokyo Japan Recruiting
Yamagata University Yamagata Japan Recruiting
Barcelona University Barcelona Spain Recruiting
Colorectal Surgery, Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona UAB Barcelona Spain Recruiting
Surgery Department, Hospital del Mar, Barcelona, Spain Barcelona Spain Recruiting
Salamanca Biomedical Research Institute Madrid Spain Recruiting
University of Salamanca-SACYL-CSIC, Salamanca, Spain Salamanca Spain Recruiting
University of La Laguna San Cristóbal de La Laguna Spain Recruiting

More City of Hope Medical Center trials in Japan

Early Detection of Advanced Adenomas and Colorectal Cancer Recruiting
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer Recruiting
Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma Recruiting
Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer Recruiting
Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma Recruiting

Other trials for the same condition

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) Active, not recruiting
Early Detection of Advanced Adenomas and Colorectal Cancer Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors Recruiting
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06342401 on ClinicalTrials.gov ↗ ← All trials in Japan